Robin Swartz sold $37k of VYGR
COO&CBO at Voyager Therapeutics, Inc.. 6,500 shares at an average of $5.65, traded Dec 23, 2024, filed Dec 26, 2024.
Score components
- +20RoleCOO
- +6Trade size$37k at market
- 0Share of holdings soldSold 5.5% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-131725, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 23, 2024 | SOpen-market sale Common Stock | -6,500 | $5.65 | $37k | 112,328 | Dec 26, 2024 |
Related signals
Other insiders at Voyager Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 3Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $16k 4,174 shares | -3% | |
| 10Weak | Voyager Therapeutics, Inc. | Nathan D. Jorgensen Chief Financial Officer | $18k 4,668 shares | -3% | |
| 3Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $11k 3,301 shares | -2% | |
| 23Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $14k 3,525 shares | -2% | |
| 8Weak | Voyager Therapeutics, Inc. | Nathan D. Jorgensen Chief Financial Officer | $37k 7,666 shares | -6% | |
| 28Weak | VYGRsell Voyager Therapeutics, Inc. | Toby Ferguson Chief Medical Officer | $71k 19,000 shares | -12% | |
| 29Weak | Voyager Therapeutics, Inc. | Toby Ferguson Chief Medical Officer | $35k 10,086 shares | -6% | |
| 39Weak | Voyager Therapeutics, Inc. | Alfred Sandrock President and CEO | $37k 10,885 shares | -2% | |
| 23Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $14k 3,305 shares | -4% | |
| 23Weak | Voyager Therapeutics, Inc. | Todd Alfred Carter Chief Scientific Officer | $24k 5,413 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.